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Human retinal pigment epithelial (hRPE) cells have been tested as a cell-based therapy for Parkinson’s disease but will require
additional study before further clinical trials can be planned. We now show that the long-term survival and neurotrophic potential
of hRPE cells can be enhanced by the use of FDA-approved plastic-based microcarriers compared to a gelatin-based microcarrier
as used in failed clinical trials. The hRPE cells grown on these plastic-based microcarriers display several important characteristics
of hRPE found in vivo: (1) characteristic morphological features, (2) accumulation of melanin pigment, and (3) high levels
of production of the neurotrophic factors pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor-
A (VEGF-A). Growth of hRPE cells on plastic-based microcarriers led to sustained levels (>1ng/ml) of PEDF and VEGF-A in
conditioned media for two months. We also show that the expression of VEGF-A and PEDF is reciprocally regulated by activation
of the GPR143 pathway. GPR143 is activated by L-DOPA (1µM) which decreased VEGF-A secretion as opposed to the previously
reported increase in PEDF secretion. The hRPE microcarriers are therefore novel candidate delivery systems for achieving long-
term delivery of the neuroprotective factors PEDF and VEGF-A, which could have a value in neurodegenerative conditions such
as Parkinson’s disease.
1.Introduction
Parkinson’s disease (PD) is the 2nd most common neu-
rodegenerative disease. Risk for PD is primarily related to
increased age, and the most vulnerable neurons are the
dopaminergic neurons in the substantia nigra. Destruction
oftheseneuronsleadstoadisruptionofthepathwaybetween
the substantia nigra and striatum and produces a severe
dopamine deﬁciency [1]. Dopamine plays an important role
in the communication between the thalamus, striatum, and
cortex. Reduction of dopamine levels leads to the cardinal
motoric features of Parkinson’s disease: tremor, generalized
slowness of movement, and diﬃculty transitioning from
one movement to the next [1]. The most eﬀective form of
treatment for PD is dopamine replacement therapy.
The two most pressing therapeutic challenges in PD
are to (1) provide a stable level of dopamine replacement
and (2) slow or halt disease progression as reviewed [2–4].
Pharmacological treatment of PD is satisfactory in the early
stages of the disease but becomes problematic as the disease
progresses. Treatment with the potent dopamine precursor
L-DOPA is eventually required for almost all patients, and its
erraticabsorptionandshorthalf-lifeleadtothedevelopment
of disabling ﬂuctuations in the treatment response [5].
Providing a continuous intracerebral source of dopamine by
using cell-based therapy has been at the front line of exper-
imental eﬀorts [6]. One strategy has been to use hRPE cells
as a local source of L-DOPA [7–11]. Cell transplantation of
hRPE using cross-linked gelatin microcarriers has been used
in preclinical and clinical studies of PD and appears to be a2 Journal of Biomedicine and Biotechnology
safe technique [8, 12, 13]. However, the therapeutic potential
for this platform has been questioned due to the recently
reported failure of the commercially sponsored Phase II
clinical trial [13]. Among the several potential contributing
factors to the lack of eﬃcacy, we would like to point out
three speciﬁcally. Firstly, there may have been a failure to
achieve long-term survival of the hRPE monolayers on the
gelatin-basedmicrocarriers.Immunesystemresponsestothe
graft may have been responsible for graft failure, and these
could be ameliorated by the use of immunosuppression in
future trials or avoided by the use of autologously produced
hRPE cultured from a small biopsy. Secondly, long-term
survival of the graft may also be hindered by digestion of
the gelatin-based microcarrier, needed to keep hRPE as a
diﬀerentiated functional monolayer. Inert plastic materials
might provide for a more stable microcarrier since these will
not be degraded. Finally, the failure to account for the role of
neurotrophic factors in the positive results seen in preclinical
and Phase 1 trials could be an important aspect. The clinical
beneﬁt found in the initial trial and previously described in
both rat and nonhuman primate models of PD [8, 14]w a s
presumed to be due to the production of L-DOPA. However,
some of the observed beneﬁt could be related to the release
of neuroprotective factors [15] such as pigment epithelium-
derived factor (PEDF) [16, 17] and vascular endothelial
growth factor-A (VEGF-A) [17]. Indeed, primate studies
of hRPE transplantation have indicated a persistent clinical
beneﬁt despite little or no long-term survival of the initial
engraftment as assessed by both behavioral and neuroimag-
ing measures [18]. These data suggest that a neurorestorative
eﬀect outlasting survival of the cell transplant was induced.
The Phase II trial design lacked screening of the cells for
normal levels of production of PEDF or VEGF-A prior to
implantation. We believe it would be a mistake to allow the
result of the single Phase II trial to prematurely halt further
development of the hRPE platform. To reinvigorate this
ﬁeld, other properties and new manipulations of hRPE cells
need to be put forth. It is in this regard that we emphasize
and further extend the important ﬁndings that (1) PEDF
and VEGF-A are neurotrophic and neuroprotective factors
i nc u l t u r em o d e l so fP D[ 17, 19], (2) the PEDF level of
hRPE cells is subject to variability depending on the source
and also the pigmentation level [20], and (3) the PEDF
level is regulated by L-DOPA via the G-protein-coupled
receptor GPR143 (OA1) [21]. Further investigations of the
neurotrophic potential of hRPE cells, due to secretion of
PEDF and VEGF-A, have the potential to revive interest in
thehRPEcellplatformascelltransplantationtherapyforPD.
However, further understanding of the regulation of these
factors in hRPE cells will be required, particularly since L-
DOPA is central to the strategy of dopamine replacement
using hRPE transplantation. A reciprocal regulation of PEDF
and VEGF-A is known in many body tissues [16, 17, 22];
for example, when VEGF-A levels are high, PEDF levels are
generally low and vice versa. Since activation of GPR143 up-
regulates PEDF production and secretion, it would be logical
to investigate if there is also a reciprocal eﬀect on VEGF-A.
Further investigation of the neurotrophic potential of
hRPE cells should be coupled with research to aid in
the development of microcarriers with increased long-term
stability. Such studies would allow the development of more
stringent criteria that could be used to screen hRPE cell lines
and predict their likelihood of robust clinical eﬃcacy. The
experiments described here take a ﬁrst step in this direction
by (1) examining the levels of PEDF and VEGF-A secretion
of hRPE on diﬀerent types of plastic-based microcarriers
and (2) investigating if there is an eﬀe c to fL - D O P Ao n
regulation of VEGF-A secretion as has been shown for
PEDF secretion.
2.MaterialsandMethods
2.1. RPE Culture. RPE cells were isolated from human
donor eyes obtained from Advanced Bioscience Resources
as described [23, 24] and maintained in Chee’s essential
medium replacement media (CEM-RM). To seed the micro-
carriers, hRPE cells (1 × 106)w e r ep l a t e di na1 2 . 5 c m 2
ﬂask coated with 3% agar and gently rocked for 2 hours
with 100µL microcarriers delivered as a 1:1 ratio (v/v)
microcarrier to media slurry, 200µL total volume. The total
number of microcarriers diﬀered among the microcarrier
types as the microcarrier size diﬀered, but the packed
volume of microcarriers was the same in each group. We
used four types: the gelatin-based CultiSpher microcarriers
(macroporous gelatin microcarriers, diameter: 130–380µm;
Percell Biolytica, Astorp, Sweden), as well as 3 plastic-based
microcarriers from Solohill Engineering (Ann Arbor MI)
that are free from animal products and FDA approved:
Hillex II (modiﬁed polystyrene with cationic trimethyl
ammonium, diameter: 160–180µm), Plastic Plus (cross-
linked polystyrene, cationic charged, diameter: 90–150µm),
and ProNectin F (trademark Solohill, polystyrene coated
with recombinant RGD containing protein, diameter 90–
150µm) microcarriers.
2.2. PTU + L-DOPA Treatment. To determine whether
GPR143 signaling activity controlled VEGF-A secretion, we
used a strategy similar to that which illustrated the receptors
control over PEDF [21]. hRPE cells were plated into 24-
well plates in CEM and maintained at conﬂuency for 3-4
months to facilitate diﬀerentiation of the monolayers [23].
Because L-DOPA is the endogenous ligand for GPR143, and
allpigmentedcellsproduceL-DOPA,weused200µMphenyl
thiourea (PTU) to inhibit the endogenous production of L-
DOPA by tyrosinase, which then downregulates the GPR143
signaling pathway, allowing us to control the signaling
pathway and use a deﬁned L-DOPA concentration. In the
presenceofPTU,wethenadded1.0µML-DOPAtostimulate
the GPR143 signaling pathway. Each treatment was on the
cells for 72 hours, after which the media was collected and
immediately frozen at −80◦C.
2.3. Photomicrography. Images were acquired digitally on
an Olympus IX70 inverted microscope and camera using
Olympus MagnaFire software using a 20x objective (400x
magniﬁcation).Journal of Biomedicine and Biotechnology 3
2.4. ELISA Measurement of VEGF-A, PEDF, GDNF, and
BDNF. Enzyme-linked immunosorbent assays (ELISAs)
were used to determine the concentrations of VEGF-A
(R&D Systems, Minneapolis, MN, USA), PEDF (Chemicon
International, Temecula, CA, USA), glial-cell-line-derived
neurotrophic factor (GDNF; Promega, Madison, WI, USA)
and brain-derived neurotrophic factor (BDNF; Promega,
Madison, WI, USA) in conditioned medium from hRPE cells
grown on microcarriers or normal tissue culture ﬂasks. The
medium was harvested from the hRPE cultures every 3-
4 days to produce the conditioned medium (CM) samples
over long-term time courses. The CM was frozen at −80◦C
immediately after harvest. The ELISAs were performed in
duplicate as directed by the manufacturers. ELISA results
were obtained using an EMAX Microtiter Plate Reader
(Molecular Devices, Downingtown PA, USA).
3. Results
3.1. Growth of hRPE on Microcarriers. The hRPE cells were
seeded onto the microcarriers and followed for 2 months
in culture. Figure 1 shows example photomicrographs of the
diﬀerent plastic-based microcarriers covered with monolay-
ers of hRPE at 1 and 2 months after seeding. Figures 1A
and 1B depict hRPE cells on Hillex II microcarriers, at 1
month and 2 months. The hRPE formed a clearly visible
monolayer around the microcarrier with the characteristic
melaninpigmentandthepolygonalmorphologyreminiscent
ofthenormalhistologicalfeaturesfoundinvivo[23].Figures
1Ca n d1D depict hRPE cells on Plastic Plus microcarriers,
and Figures 1Ea n d1F depict hRPE cells on ProNectin
F microcarriers. From the visual inspection, the Hillex II
microcarriers appear to have the most uniform monolayer,
but all microcarriers had signiﬁcant clumping. The hRPE
cells remained as a monolayer on the Hillex II microcarrier
mostfrequently.ThehRPEcellsonthePlasticPlusmicrocar-
riers generally appeared as an amorphous mass of cells and
microcarriers as illustrated. The hRPE cells on the ProNectin
F microcarriers were generally present as a monolayer but
not as regular as on the Hillex II microcarriers.
3.2. PEDF Concentration Time Course. The PEDF present
in hRPE media was measured in a series of ELISAs. In all,
the ELISA results show a signiﬁcant PEDF secretion into the
medium by hRPE cells over 2 months.
For each of the four types of microcarrier with monolay-
ers of hRPE cells, the PEDF concentration was measured for
samples collected every few days for 2 months, as shown in
Figure 2. The cells on the CultiSpher microcarrier secreted
insigniﬁcant amounts of PEDF. This was explained by the
inability of the CultiSpher to create a suﬃcient base for
hRPE cells to form a healthy monolayer. The other three
microcarrier types, Hillex II, Plastic Plus, and ProNectin F
all cultured with hRPE from the same donor eye, provided
comparable PEDF levels. After a short rising phase, maximal
expression levels were reached at about 3-4ng/mL from the
Hillex II microcarriers and about 2ng/mL from Plastic Plus
and ProNectin F microcarriers, and the PEDF concentration
remained stable for the duration of the experiment (2
months) as shown in Figure 2.
3.3. VEGF-A Concentration Time Course. The VEGF-A
present in hRPE media was measured in a series of ELISAs.
In all, the ELISA results show a signiﬁcant VEGF-A secretion
into the medium by hRPE cells over time.
For each of the four types of microcarrier with monolay-
ers of hRPE cells, the VEGF-A concentration was measured
for samples collected every few days for 2 months, as
shown in Figure 3. The cells on the CultiSpher microcarrier
secreted insigniﬁcant amounts of VEGF-A, which again
was attributed to largely unsuccessful growth of cultures
of hRPE cells on CultiSpher over time. The other three
microcarrier types Hillex II, Plastic Plus, and ProNectin F,
provided comparable VEGF-A levels. After a rising phase
of about 20 days, stable expression levels were reached at
about 15ng/mL, and the VEGF-A concentration remained
stable for the duration of the experiment (2 months) as
shown in Figure 3. The higher variability within the PEDF
versus the VEGF-A time course is explained by the fact that
the PEDF concentration measured is much closer to the
detection threshold than the VEGF-A concentration.
3.4. GDNF and BDNF Concentration Time Course. The
GDNF present in hRPE media was measured in a series of
ELISAs. In all, the ELISA results showed a signiﬁcant GDNF
secretion into the medium by hRPE cells grown on Hillex
II, Plastic Plus, and ProNectin F microcarriers only over the
ﬁrst 3 weeks as depicted in Figure 4. After day 22 the GDNF
level had dropped below the detection threshold. Even at
the start, the GDNF concentration was only in the pg/mL
range, compared to VEGF-A and PEDF for which ng/mL
concentrations were measured.
We also examined if BDNF was present in hRPE media
as measured in a series of ELISAs. In all, the ELISA results
showed that the hRPE cells did not secrete any measurable
BDNF into the medium on all microcarriers tested at any
time point (data not shown).
3.5. Regulation of Neurotrophic Output of hRPE. We have
previously shown that GPR143 signaling regulates PEDF
production in hRPE cells [21]. To extend this ﬁnding, we
investigated regulation of VEGF-A output in hRPE cells,
using the tissue-type, stable, pigmented monolayer for a
minimum of 3 months prior to experiment initiation. We
used the same paradigm used by Lopez et al. 2009 [21]
to deﬁne PEDF regulation in hRPE cells. The tyrosinase
inhibitor PTU was used to block endogenous L-DOPA
production and allow control of OA1 signaling without
complicated endogenous activity. We added 200µMP T U+
1µM L-DOPA which caused a signiﬁcant decrease in VEGF-
A production that was restored to baseline when L-DOPA
was removed. This decrease of VEGF-A production after
addition of L-DOPA compared to the untreated cells (P<
0.0005, paired t-test with Bonferroni Correction, n = 9) is
showninFigure 5.AftertheL-DOPAwasremoved,therewas4 Journal of Biomedicine and Biotechnology
Figure 1: Example photomicrographs for hRPE cells grown on diﬀerent plastic-based microcarrier types at 1 month (A, C, E) and two
m o n t h s( B ,D ,F ) .H i l l e xI Im i c r o c a r r i e r sa r es h o w ni nAa n dB ,P l a s t i cP l u sm i c r o c a r r i e r sa r es h o w ni nCa n dD ,a n dP r o N e c t i nF
microcarriers are illustrated in E and F. Note the characteristic melanin pigment and the polygonal morphology reminiscent of the normal
histological features found in vivo. Scale bar = 100µm.
a signiﬁcant increase of VEGF-A production (P<0.0005,
paired t-test with Bonferroni Correction, n = 9) by the
cells, returning toward baseline. The comparison of the cells
at baseline and after the washout period (paired t-test with
Bonferroni’s correction, n = 9) shows no signiﬁcant change
in VEGF-A concentration.
4. Discussion
RPE cells have been studied as a transplantation platform
for the treatment of PD based on their ability to produce L-
DOPA as intermediate in the melanin synthesis pathway and
thus provide a source of continuous intracerebral dopamineJournal of Biomedicine and Biotechnology 5
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Figure 2: PEDF concentration time course. The PEDF concentra-
tion in the media from the hRPE cells on the diﬀerent microcarriers
was measured with an ELISA. After a short rising phase the PEDF
concentration reached a plateau. ThehRPEcells onHillex II,Plastic
Plus,andProNectinFmicrocarrierssecretedcomparableamountof
PEDF, whereas hRPE cells on the CultiSpher microcarriers did not
secrete signiﬁcant amounts of PEDF.
replacement. In their normal anatomical location, RPE cells
function to facilitate retinal survival and activity, in part by
the secretion of the neurotrophic factors PEDF and VEGF-
A[ 17, 25, 26] .T h e s ef a c t o r sc o u l dp o t e n t i a l l yp r o v i d ea n
additional beneﬁt in PD by virtue of neuroprotective eﬀects
ondopaminergicneurons.Bothofthesemoleculeshavebeen
extensively studied with regard to their role in controlling
tissue vascularity, where they have opposing eﬀects to either,
respectively, inhibit or promote angiogenesis [16, 17, 26].
In addition to their role in controlling angiogenesis, recent
studies have supported an important neurotrophic function
for both molecules in the CNS where they may work in
concert [17].
Neuroprotective action of PEDF has also been described
in a variety of neuronal cell types grown in vitro as well
as in a postnatal organotypic culture model of motor
neurondegeneration[27,28].PEDFpreventedthedeathand
atrophy of spinal motor neurons in vivo in the developing
neonatal mouse after axotomy [29]. Of importance for the
currentstudy,PEDFhasbeenshowntobebothneurotrophic
and neuroprotective in two in vitro models of PD [19].
It has been shown that VEGF-A has neurotrophic and
neuroprotective properties in explants of the ventral mes-
encephalon [30]. VEGF-A has been shown to cause axonal
outgrowth on cultured ganglia in a dose-responsive manner
[31]. At VEGF-A concentrations (10–50ng/mL) comparable
to the level found in hRPE-conditioned media in this study,
neuroprotective eﬀects have been observed on cultured cells
subjected to hypoxia and glucose deprivation [32]. Unfor-
tunately, at higher concentrations, because of its angiogenic
nature, VEGF-A may cause increased permeability of the
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Figure 3: VEGF-A concentration time course. The VEGF-A
concentration in the media from the hRPE cells on the diﬀerent
microcarriers was measured with an ELISA. After a rising phase in
the ﬁrst 20 days after seeding the VEGF-A, concentration reached
a plateau and remained stable until the end of the experiment. The
hRPE cells on Hillex II, Plastic Plus, and ProNectin F microcarriers
secreted comparable amount of VEGF-A, whereas hRPE cells on
the CultiSpher microcarriers did not secrete signiﬁcant amounts of
VEGF-A.
blood-brain barrier, which could be detrimental in causing
cerebral edema or other untoward eﬀects [33]. If hRPE cells
are to be implanted in the brains of PD patients as a therapy,
it will be important to establish that VEGF-A production is
suﬃcient for neuroprotection but below the threshold for
disruption of the blood-brain barrier.
The combined neurotrophic eﬀects and the exact ratio of
PEDF and VEGF-A could also be important considerations.
A possible concerted neurotrophic eﬀect by PEDF and
VEGF-A in PD was suggested by Yasuda et al. [34] reporting
a signiﬁcantly positive correlation in the striatal levels of
PEDF and VEGF-A in brains acquired at autopsy in PD
patients.ThisstudyalsomonitoredthestriatallevelsofPEDF
relative to the VEGF-A levels in a rodent model following
a toxic insult to the dopaminergic pathway. Acute damage
to dopaminergic neurons induced a rise in PEDF levels in
the CNS, supporting the hypotheses that PEDF acts as an
endogenous natural neuroprotective response factor.
In this study we found that hRPE cells grown on plastic-
based microcarriers retain their ability to produce both
PEDF and VEGF-A, but we were unable to produce long-
term cultures of hRPE cells on gelatin-based CultiSpher
microcarriers. Thus, by virtue of the cells failing after initial
attachment, we did not observe signiﬁcant levels of either
neurotrophic factor with those microcarriers. The hRPE
cells transplanted in the Spheramine clinical trials utilized
gelatin-based Spheramine microcarriers, and their potential
to produce PEDF and VEGF-A was never investigated. The
extent to which neuroprotection is operative in clinical trials6 Journal of Biomedicine and Biotechnology
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Figure 4: GDNF concentration time course. The GDNF concentra-
tion in the media from the hRPE cells on the diﬀerent microcarriers
was measured with an ELISA. The hRPE cells on Hillex II, Plastic
Plus, and ProNectin F microcarriers secreted comparable amounts
o fG D N Fa tt h es t a r to ft h et i m ec o u r s e .T h ec o n c e n t r a t i o nw a sa n
order of magnitude less when compared to VEGF-A and PEDF. The
GDNF concentration declined over the ﬁrst 3 weeks, and there was
no detectable amount of GDNF from day 22 on.
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Figure 5: Regulation of VEGF-A expression in hRPE cells.
Treatment of hRPE monolayers, grown in 24-well plates, with
PTU (a tyrosinase blocker used to eliminate endogenous L-DOPA
production) and 1µM L-DOPA leads to a decrease in VEGF-A
concentration in the medium. After washout of PTU and L-DOPA,
the VEGF-A concentration returns to the baseline levels. Data are
presented as the mean of three experiments conducted in triplicate,
error bars represent S.E.M., and an asterisk (∗)d e n o t e sP<0.0005
using paired t-tests with Bonferroni’s correction between the PTU
+ L-DOPA group from both the baseline and the washout groups.
of hRPE transplantation remains speculative, but is in our
opinion deserving of due consideration.
Additional reasons must also be considered to explain
the failure of the Phase II clinical trial to show eﬃcacy [13]
despite promising preclinical [8–10, 14] and Phase I clinical
trials [12]. Subsequent pathology data showed that most
cells did not survive implantation for more than 6 months
[35], raising doubts about the long-term stability of the
graft. Since one of the potential pitfalls of the clinical trial
is that the gelatin-based Spheramine microcarriers might
have been digested over time, we investigated nondegradable
microcarriers in their potential to provide healthy hRPE
growth, survival, and neurotrophic output [20, 36]. Culti-
Spher microcarriers were ineﬀective in achieving healthy
hRPE monolayers as evidencedby the lackof pigmented cells
covering the microcarriers. Thus, it was not surprising that
little PEDF or VEGF-A was produced using that substrate.
Plastic Plus, ProNectin F, and Hillex II microcarriers on
the other hand all have potential as microcarriers for hRPE
growth and potential implantation. The hRPE cells appeared
themostdiﬀerentiated,pigmented,andregularinheightand
thickness on the Hillex II microcarriers. Interestingly, both
the PEDF (2–4ng/mL) and the VEGF-A (15ng/mL) outputs
of the hRPE cells on all three plastic-based microcarriers
were very similar throughout the two-month time course,
even though the appearance of the cultures was signiﬁcantly
diﬀerent. We did not investigate the neurotrophic eﬀect
of the hRPE cells grown on microcarriers in this study,
but based on our prior study evaluating the neurotrophic
potential of conditioned media (RPE-CM) from 2-month-
old fully diﬀerentiated hRPE cultures before and after PEDF
depletion [20], we can conclude that over 50% of the
neurotrophic eﬀect on cultured neurons that was produced
by hRPE cells is due to PEDF production. We can speculate
that the remainder of that eﬀect can be mostly attributed to
VEGF-A, since we showed in the current study that VEGF-A
is secreted throughout the study at signiﬁcant levels whereas
the hRPE cells do not produce measurable amount of BDNF
at any time point (data not shown), and the GDNF level
(Figure 4) drops below detection threshold by the 3rd week
of culture.
Inaparallelexperiment,weinvestigatedtheregulationof
the neurotrophic output in hRPE cells by L-DOPA. An inter-
esting facet of the regulation of PEDF secretion is the linkage
to an autocrine loop that regulates tyrosinase activity and
pigmentsynthesisutilizingL-DOPAandGPR143.GPR143is
a G-Protein-coupled receptor with highest expression levels
found in RPE cells. GPR143 signaling is critical for full
expression of the L-DOPA synthetic enzyme tyrosinase. L-
DOPA is not only a precursor for the formation of melanin,
but also acts to increase melanogenesis by activating the
GPR143 receptor creating a positive feedback loop. Loss of
GPR143 signaling also reduces the output of PEDF from
RPE cells. Genetic defects in GPR143 cause ocular albinism,
a disorder of pigmentation that leads to vision loss due to
changes in retinal neuron development and survival. The
exact cause of the secondary neuronal loss observed in this
disorder has been debated, but may reﬂect the decremental
changes in PEDF production and subsequent loss of retinal
neurotrophism.
A better understanding of the inﬂuence of L-DOPA
on the neurotrophic output of RPE cells is also required
for the potential use of RPE cell transplantation in PD.
Since there is a reciprocal “yin and yang” like eﬀect of
PEDF and VEGF-A regulation [17], at work in many cellJournal of Biomedicine and Biotechnology 7
types, including the eye, we sought to test whether GPR143
signaling, which upregulates PEDF secretion from hRPE
cells, may downregulate VEGF-A secretion. To test this we
used the same experimental method used previously to
illustrate upregulation of PEDF by GPR143 signaling [21].
VEGF-A secretion was reduced signiﬁcantly by induction of
GPR143 signaling using the PTU/L-DOPA paradigm. Thus,
we suggest that in hRPE cells, GPR143 up-regulates PEDF
while simultaneously downregulating VEGF-A. In addition
to the advance in the ﬁeld of RPE cell transplantation, this
observation has signiﬁcant implications for our understand-
ingofpigmentation-relatedeyediseasessuchasalbinismand
age-related macular degeneration.
Overall, it is apparent that hRPE cells grown on plastic-
based microcarriers produce levels of both PEDF and VEGF-
A that are in a range that would support a neuroprotective
eﬀect. The levels of PEDF (maximum around 4ng/mL) were
higher than the 1ng/mL PEDF that was reported to be
neuroprotective in both 6-OHDA and rotenone rat midbrain
culture models [19]. In this paper we show that the secretion
of VEGF-A is downregulated by L-DOPA. This eﬀect was
partial (less than 15%) and did not eliminate VEGF-A
secretion under any conditions tested. The levels of VEGF-
A (maximum around 15ng/mL) are suﬃcient to expect
an e u r o p r o t e c t i v ee ﬀect, since 1ng/mL VEGF-A has been
shown to provide a maximal protection in a 6-OHDA model
of PD [33]. The VEGF-A levels also appear to be low enough
that the negative eﬀect of increased vessel formation may not
be an issue. In rodent models, pathological vasculogenesis
was observed after implantation of BHK cells expressing
VEGF-A at approximately 40ng/mL [33]. It is important
to note that future manipulation of the GPR143 pathway
could be used to optimize and balance the neurotrophic
production of hRPE cells.
In future work the plastic-based hRPE microcarriers
should be tested in vivo employing rodent models of
neurodegeneration, to evaluate the long-term survival of the
hRPE and the continued ability to release therapeutically
relevantamountsofPEDFandVEGF-Aaftertransplantation
into the brain. The relative contribution of PEDF versus
VEGF-A to the expected neurotrophic eﬀects should also be
further investigated in vivo.
5. Conclusion
Human RPE cells can be successfully grown and diﬀeren-
tiated on 3 diﬀerent types of FDA-approved plastic-based
microcarriers over an extended period of time. The hRPE
microcarriers produce signiﬁcant amounts of two growth
factors with neuroprotective potential, PEDF and VEGF-A.
The regulation of both factors can be reciprocally regulated
by modulation of the GPR143/OA1 pathway.
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